Item 1.01 Entry Into a Material Definitive Agreement.

On September 30, 2021, Emergent BioSolutions Inc. (including its wholly-owned subsidiaries, "Emergent"), through its wholly-owned subsidiary, Emergent Product Development Gaithersburg Inc., received a contract modification ("Modification No. 11") to the AV7909 development and procurement contract with the Biomedical Advanced Research and Development Authority ("BARDA"), a component of the Office of the Assistant Secretary for Preparedness and Response, ("ASPR"), an agency of the U.S. Department of Health and Human Services. Modification No. 11 seeks to procure additional doses of AV7909 (anthrax vaccine adsorbed with adjuvant) for delivery into the Strategic National Stockpile, valued at approximately $399 million, with deliveries over the next 18 months.

The preceding description of the modification described herein does not purport to be complete and is qualified in its entirety by reference to the full text of the actual modification. The modification, with relevant redactions to protect confidential and sensitive information, is expected to be filed as an exhibit to Emergent's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2021.

© Edgar Online, source Glimpses